Amgen Inc. (AMGN) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
Amgen Inc. (AMGN) Profile & Business Summary
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Key Information
| Ticker | AMGN |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.amgen.com |
Market Trend Overview for AMGN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-10-01 (ET)
As of 2026-10-01, AMGN is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
AMGN last closed at 407.27. The price is about 0.5 ATR below its recent average price (411.65), and the market is currently in a sideways market without a clear direction. Price at 407.27 is moving between minor support near 375.96 and minor resistance near 415.76. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear key risk boundary right now.
A systematic trend-activation signal was most recently triggered on 2026-09-25, reflecting a technical shift toward positive directional alignment.
[2026-09-25] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not deploy this setup because price is still close to a gamma transition zone. Predictability is 36%, agreement is 68%, and reversal risk is 22%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 50 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-10-01. The current price is 407.27, 0.50% above the estimated average cost of 405.24. An estimated 52.9% of recent positioning is below the current price, while 46.7% is above it. The peak-density price is 379.00. The largest concentrated cost region is 375.30 to 383.90 and contains 22.1% of the estimated distribution. The current price is within the 404.70 to 408.30 cost region. The nearest region below the current price is 395.70 to 395.90. The nearest region above the current price is 408.90 to 418.50.
Short Interest & Covering Risk for AMGN
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 58%)
Structure Analysis
AMGN Short positioning looks normal. Current days to cover is 4.9 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. Price is already trending lower (20D return -8.0%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-09-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.